Vipin K. Garg, Ph.D., is the Chief Executive Officer at Altimmune, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for liver diseases and immuno-oncology. Dr. Garg brings extensive experience in the biopharmaceutical industry, having held leadership positions at several prominent companies. Before joining Altimmune, he served as President and Chief Executive Officer of Proteostasis Therapeutics, where he led the company's efforts in developing treatments for cystic fibrosis and other diseases caused by protein misfolding. Prior to that, he spent over a decade at Gilead Sciences, where he played a key role in the development and commercialization of groundbreaking antiviral therapies, including Sovaldi and Harvoni for the treatment of hepatitis C. Under Dr. Garg's leadership, Altimmune has made significant strides in advancing its pipeline of novel therapies. He has been instrumental in guiding the company's lead product candidate, pemvidutide, through clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. Dr. Garg's strategic vision and deep understanding of the biopharmaceutical landscape have enabled Altimmune to forge key partnerships and secure funding to support its research and development efforts. His commitment to innovation and patient-centric drug development has positioned Altimmune as a leader in the field of liver disease and immuno-oncology. As CEO of Altimmune, Dr. Garg is responsible for overseeing the company's overall strategy, operations, and growth. He leads a talented team of scientists, clinicians, and business professionals in their mission to develop transformative therapies that address unmet medical needs. Dr. Garg's strong leadership skills, coupled with his extensive experience in drug development and commercialization, make him an invaluable asset to Altimmune as the company continues to advance its pipeline and bring new treatments to patients worldwide.